<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="20912">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02834650</url>
  </required_header>
  <id_info>
    <org_study_id>DMD2016</org_study_id>
    <nct_id>NCT02834650</nct_id>
  </id_info>
  <brief_title>Validating Cardiac MRI Biomarkers and Genotype-Phenotype Correlations for DMD</brief_title>
  <official_title>Validating Cardiac MRI Biomarkers and Genotype-Phenotype Correlations for Duchenne Muscular Dystrophy (DMD)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, Los Angeles</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institutes of Health (NIH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Childrenâ€™s Hospital of Orange County</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of California, Los Angeles</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will collect MRI from healthy volunteer boys and boys with Duchenne Muscular
      Dystrophy (DMD) to help researchers identify and validate cardiac MRI biomarkers to better
      understand the health of the heart and changes in heart health over time in boys with DMD.

      Currently, there is a lack of sufficiently well characterized cardiac MRI biomarkers that
      can serve as endpoints for detecting on-target and/or off-target cardiac effects during
      clinical drug trials for boys with DMD.

      Consequently, the first objective is to identify and characterize several cardiac MRI
      biomarkers for boys with DMD.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The second objective is to use their well-characterized cardiac MRI biomarkers and define
      their sensitivity for detecting early cardiac involvement. The final objective is to use
      these validated cardiac MRI biomarkers to better understand the genotype-phenotype
      correlation in boys with DMD, which to date remain tenuous. The investigators propose a
      pilot study to explore cardiac genotype-phenotype correlations in boys with DMD and outlier
      phenotypes using approaches they have pioneered for skeletal muscle.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2017</start_date>
  <completion_date type="Anticipated">October 2020</completion_date>
  <primary_completion_date type="Anticipated">January 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Myocardial Tissue Characterization</measure>
    <time_frame>6 months</time_frame>
    <description>Focal and diffuse fibrosis, intra myocardial fat, edema plus water mobility</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Myocardial Functional Characterization</measure>
    <time_frame>6 months</time_frame>
    <description>Strain imaging and rotational mechanics</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Genomic Analysis</measure>
    <time_frame>4 years</time_frame>
    <description>Proposing mechanisms of cardiac dysfunction or protective phenotypes using genomic analysis</description>
  </primary_outcome>
  <number_of_groups>4</number_of_groups>
  <enrollment type="Anticipated">154</enrollment>
  <condition>Muscular Dystrophy, Duchenne</condition>
  <arm_group>
    <arm_group_label>Group 1a</arm_group_label>
    <description>Group 1a comprises healthy volunteers who will complete a Cardiac MRI without contrast. A subset of healthy volunteers will have a repeat MRI at Children's Hospital of Orange County.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 1b</arm_group_label>
    <description>Group 1b comprises boys with DMD who will complete a Cardiac MRI with contrast, a blood test, a heart rate test and a pulmonary function test.
A subset of boys with DMD will have a repeat MRI with contrast at Children's Hospital of Orange County.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2</arm_group_label>
    <description>Group 2 comprises boys with DMD who will complete a Cardiac MRI with contrast, a blood test, a heart rate test and a pulmonary function test and a repeat MRI scan with contrast at 6 Months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 3</arm_group_label>
    <description>Group 3 comprises boys with DMD who will complete a Cardiac MRI with contrast, a blood test, a heart rate test and a pulmonary function test and a genetic testing.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Cardiac MRI with contrast</intervention_name>
    <description>Cardiac MRI</description>
    <arm_group_label>Group 1b</arm_group_label>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_label>Group 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Cardiac MRI without contrast</intervention_name>
    <description>Cardiac MRI</description>
    <arm_group_label>Group 1a</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Blood Test</intervention_name>
    <description>Hematocrit, Creatinine, Troponin, BNP</description>
    <arm_group_label>Group 1b</arm_group_label>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_label>Group 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Heart Rate</intervention_name>
    <description>Holter Monitor</description>
    <arm_group_label>Group 1b</arm_group_label>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_label>Group 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Pulmonary Function Test</intervention_name>
    <description>Pulmonary Function Test</description>
    <arm_group_label>Group 1b</arm_group_label>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_label>Group 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Genetic Testing</intervention_name>
    <description>Genetic Testing</description>
    <arm_group_label>Group 1b</arm_group_label>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_label>Group 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Repeat MRI scan</intervention_name>
    <description>Repeat MRI scan</description>
    <arm_group_label>Group 1a</arm_group_label>
    <arm_group_label>Group 1b</arm_group_label>
    <arm_group_label>Group 2</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Boys with DMD in all groups will have a blood test. In addition to the blood test group 3
      will have a genetic testing.
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Boys with DMD and healthy volunteers.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy boys or pediatric patients with DMD age 7 to 21

          -  Able &amp; willing to complete an approximately 75-minute (or less) MRI exam without
             sedation or mechanical ventilation

          -  Drug regimen (if applicable) stable for at least 3 months prior to participation

        Exclusion Criteria:

          -  Renal insufficiency (GFR&lt;40 mL/min/m2)

          -  Non-MRI compatible implants (e.g. neurostimulator, pacemaker, implanted cardioverter
             defibrillator)

          -  Claustrophobia that prevents an MRI exam

          -  Known allergy to MRI contrast agents

          -  Serum potassium level of &gt;5.0 mmol/L

          -  Signs and symptoms of heart failure
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>7 Years</minimum_age>
    <maximum_age>21 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Daniel Ennis, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, Los Angeles</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Saima Chaabane, PhD</last_name>
    <phone>310-794-8995</phone>
    <email>schaabane@mednet.ucla.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Polly Kay, RN, CCRP</last_name>
    <phone>310-794-0376</phone>
    <email>pkay@mednet.ucla.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of California, Los Angeles</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90024</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Saima Chaabane, PhD</last_name>
      <phone>310-794-8995</phone>
      <email>schaabane@mednet.ucla.edu</email>
    </contact>
    <contact_backup>
      <last_name>Polly Kay, RN</last_name>
      <phone>310-794-0376</phone>
      <email>pkay@mednet.ucla.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Daniel Ennis, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Orange County</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pierangelo Renella, MD</last_name>
      <phone>714-509-3939</phone>
      <email>prenella@choc.org</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2017</verification_date>
  <lastchanged_date>February 8, 2017</lastchanged_date>
  <firstreceived_date>July 13, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of California, Los Angeles</investigator_affiliation>
    <investigator_full_name>Daniel Ennis, PhD</investigator_full_name>
    <investigator_title>PhD</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Muscular Dystrophies</mesh_term>
    <mesh_term>Muscular Dystrophy, Duchenne</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
